For the quarter ended December 2023, Bausch Health (BHC) reported revenue of $2.41 billion, up 9.8% over the same period last year. EPS came in at $1.15, compared to $1.02 in the year-ago quarter.The reported revenue represents a surprise of +7.15% over the Zacks Consensus Estimate of $2.25 billion. With the consensus EPS estimate being $1.01, the EPS surprise was +13.86%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street e ...

Bausch Health (BHC) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $1.02 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 13.86%. A quarter ago, it was expected that this drugmaker would post earnings of $0.92 per share when it actually produced earnings of $1.03, delivering a surprise of 11.96%.Over the last four quarters, the company h ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Bausch Health (BHC) , which belongs to the Zacks Medical - Generic Drugs industry, could be a great candidate to consider.This drugmaker has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 9.98%.For the most recent quarter, Bausch was expected to p ...

8 | Page Adjusted EBITDA attributable to Bausch Health (non-GAAP) is Adjusted EBITDA (non-GAAP) further adjusted to exclude the Adjusted EBITDA attributable to noncontrolling interest (non-GAAP). Adjusted EBITDA attributable to noncontrolling interest (non-GAAP) is Net income attributable to noncontrolling interest (its most directly comparable GAAP financial measure) adjusted for the portion of the adjustments described above attributable to noncontrolling interest. significantly impacted by the timing and ...

Revenue and Financial Performance - Total revenues for 2023 were $8,757 million, an increase from $8,124 million in 2022 and $8,434 million in 2021[27]. - The Salix segment generated $2,250 million in revenue for 2023, maintaining a 26% share of total revenues, consistent with 2022[27]. - The Bausch + Lomb segment accounted for $4,146 million in revenue, representing 47% of total revenues, up from 46% in 2022[27]. - Xifaxan product revenues were $1,810 million in 2023, compared to $1,692 million in 2022 and $1,644 million in 2021[30]. - In 2023, the U.S. and Puerto Rico accounted for approximately 59% of total revenue, while China accounted for approximately 5%[78]. - Cencora Inc. accounted for 19% of total revenue in 2023, followed by McKesson Corporation at 15% and Cardinal Health, Inc. at 13%[79]. Research and Development - The company is focusing on R&D to enhance its product portfolio and is exploring co-promotions, licensing agreements, and strategic acquisitions[26]. - R&D expenses for 2023 were $604 million, representing approximately 7% of revenue, up from $529 million (7%) in 2022 and $465 million (6%) in 2021[45]. - The company has over 90 R&D projects in the pipeline, supported by approximately 1,450 dedicated R&D and quality assurance employees[44]. - CABTREO Topical Gel, a new acne treatment, received FDA approval and is set to launch in Q1 2024[39]. - MIEBO, the first FDA-approved eye drop targeting tear evaporation, was launched in the U.S. in Q3 2023[42]. Market and Competitive Landscape - The company faces increased competition from generic pharmaceutical products as patents expire, leading to potential price reductions[85]. - The company is impacted by global economic conditions, including inflation and foreign currency exchange volatility, which may affect revenues and expenses[704]. - The company is facing risks related to the introduction of generic competitors, particularly for its Xifaxan product line, which could significantly impact revenues[704]. Regulatory and Compliance - The company is subject to extensive regulations regarding the research, development, and marketing of its products, requiring substantial time and financial resources[50]. - Compliance with the U.S. Foreign Corrupt Practices Act and similar laws is mandatory, with violations potentially leading to significant penalties[58]. - The company is subject to various state, federal, and international laws regarding the processing of health-related and personal information, including HIPAA, which mandates uniform standards for electronic information exchange[59]. - The GDPR imposes strict obligations on the processing of personal data, with potential fines of up to 4% of global annual revenue or €20 million for violations[62]. - The company is subject to environmental regulations that could result in substantial fines or penalties if compliance is not maintained[76]. Operational Efficiency and Manufacturing - The company operates approximately 37 manufacturing sites worldwide, with 25 being Bausch + Lomb facilities[87]. - In 2023, 25% of product sales were produced in total or in part by third-party manufacturers[91]. - The company continues to invest in its manufacturing facilities to enhance operational capabilities[87]. Financial Obligations and Liabilities - As of December 31, 2023, the company had $15,108 million in fixed rate debt and $5,899 million in variable rate debt[642]. - A 1% change in foreign currency exchange rates would have impacted the shareholders' deficit by approximately $62 million[639]. - The company faces substantial debt obligations and potential future indebtedness, impacting its financial condition and cash flows[700]. - The company is subject to various loss contingencies, which may materially affect its financial condition and cash flows[687]. Goodwill and Impairment - The company recorded goodwill impairment charges of $493 million in 2023, $824 million in 2022, and $469 million in 2021[663]. - The carrying value of the Generics reporting unit exceeded its fair value as of October 1, 2023, leading to a recognized goodwill impairment[676]. - The Dermatology reporting unit experienced a goodwill impairment of $151 million due to lower realized pricing and increased market interest rates, with a long-term growth rate of 0.0% and a discount rate of 10.75% used in the assessment[671]. Strategic Initiatives and Future Outlook - The company is committed to improving access to medications through patient assistance programs, providing eligible patients with prescription products at no cost for up to one year[109]. - The company is evaluating the potential effects of macroeconomic factors, including inflation, on its business operations[698]. - The company anticipates uncertainties associated with the launch of new products, including the Blink product line and MIEBO, affecting market acceptance and demand[701]. - The company is working to stabilize its Dermatology business, focusing on the success of recently launched products and pipeline approvals[702].

We are in the last leg of the fourth-quarter 2023 reporting cycle and a lot of pharma and biotech bigwigs have already reported results. The picture looks reasonably good. Bellwether J&J reported strong fourth-quarter results, wherein its earnings and sales beat their respective estimates. Swiss pharma giant Novartis’ sales and earnings lagged their respective estimates.Among the biotechs, Biogen reported lower-than-expected results for the fourth quarter, as both its earnings and sales missed estimates. Gi ...

Wall Street analysts forecast that Bausch Health (BHC) will report quarterly earnings of $1.01 per share in its upcoming release, pointing to a year-over-year decline of 1%. It is anticipated that revenues will amount to $2.25 billion, exhibiting an increase of 2.4% compared to the year-ago quarter.The consensus EPS estimate for the quarter has been revised 1.3% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial es ...

Wall Street expects a year-over-year decline in earnings on higher revenues when Bausch Health (BHC) reports results for the quarter ended December 2023. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on February 22, 2024, might help the stock move higher if these key numbers are better than ...

Bausch Health (BHC) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the syst ...

Here are three stocks with buy rank and strong value characteristics for investors to consider today, February 7:Mitsui & Co., Ltd. (MITSY) : This investment and trading company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 4.8% over the last 60 days.Mitsui & Co., Ltd. has a price-to-earnings ratio (P/E) of 8.84 compared with 21.60 for the industry. The company possesses a Value Score of A.J Sainsbury plc (JSAIY) : This diversified retail an ...